Epidemiology
Idiopathic Sudden Sensorineural Hearing Loss (SSNHL) was first described in 1944 (1) and is characterized by new onset unilateral hearing loss that develops within 72 hours. There is virtually always some degree of associated aural fullness and tinnitus. Imbalance or vertigo is reported in 28 to 57 percent of cases (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Idiopathic SSNHL has an estimated incidence of 5 to 20 per 100,000 persons per year (3) . This is approximately the same incidence as Ménière's syndrome (15 per 100,000), an order of magnitude more common than acoustic neuroma (1 per 100,000), and about one-fifth the incidence of head and neck cancer (75 per 100,000)(NIH-NIDCD Health Information website). Spontaneous recovery has been reported in from 32 percent (12) to 65 percent (4) of untreated or placebo-treated cases. Simmons has speculated that overall incidence is likely underestimated, as many who recover quickly will never seek medical attention (13) . There is evidence of a window of opportunity during which treatment with oral corticosteroids can increase recovery of hearing. However, because aural fullness is such a common sensation, patients often delay treatment for days or weeks before seeking medical attention. When they finally contact a physician's office, it is not uncommon for them to be advised to try an overthe-counter decongestant for two or three weeks, further delaying appropriate treatment. Patients would be better served if the symptom of aural fullness was generally recognized as a possible indication of SSNHL and treated as an otologic emergency. In the United States, care of SSNHL by otolaryngologists typically consists of a short (Յ4 wk) course of oral corticosteroids initiated as soon as possible after onset of symptoms. This article will describe the audiometric presentation and outcomes for a 10-year retrospective series of 318 patients diagnosed with SSNHL.
Etiology
Many mechanisms have been proposed for SSNHL. The most popular theories invoke vascular or viral etiologies (3). In fact, both of these mechanisms probably do occur. However, evidence to support these theories is circumstantial. Three types of circumstantial evidence support the vascular theory of SSNHL: Sudden onset suggestive of infarction (14) ; case reports of sudden deafness in association with known systemic vascular disease (3); and histopathologic demonstration of cochlear changes due to vascular occlusion in animal models (14) . However, human temporal bone studies of SSNHL have not demonstrated labyrinthine ossification, the hallmark of labyrinthine ischemia (15, 16) .
There are four types of direct and indirect evidence for the viral theory of SSNHL: Several authors have shown a temporal association of SSNHL with active viral upper respiratory illness (17) (18) (19) ; patients with SSNHL have been shown to also have antibody titers to several viruses (20) (21) (22) ; and histopathologic examination of postmortem human temporal bones have shown atrophy of the organ of Corti, spiral ganglion, and tectorial membrane, unraveling of myelin, and relative preservation of spiral ganglion cells, findings consistent with viral deafness (15, 16) . Finally, animal experiments have demonstrated virus penetration of the inner ear (23). It is not necessary for actual viral infection of the cochlea to occur to provide a viral-based mechanism for SSNHL. Adams has shown that inflammatory cytokines produced in response to viral disease may interrupt the gap junction ion pathways in the cochlea, resulting in suddenly decreased function and eventual death of hair cells (24) . This study also demonstrated that early introduction of steroids could effectively reverse this process.
Treatment
Most of the treatments studied in randomized controlled trials can be divided into three different categories: 1) corticosteroid treatment; 2) specific antiviral therapy; and 3) specific treatment of vascular insufficiency. The justification for steroid treatment is based upon a presumed inflammatory process within the inner ear. Such inflammation might arise from a viral infection, an autoimmune mechanism, or even as a sequel of autolytic changes surrounding an area of ischemia or infarction. In other words, steroid therapy is non-specific and may be beneficial in cases of differing etiologies. The most often cited randomized controlled trial of SSNHL therapy was by Wilson et al. (12) . In this trial, 67 SSNHL patients at two clinical sites were randomized to receive oral steroids or placebo. Overall, 32 percent of the placebo group had hearing improvement, compared with 61 percent in the steroid group. Subjects with thresholds of Յ40 dB or mid-frequency ("U-shaped") losses of up to 85 dB invariably had excellent hearing recovery regardless of treatment assignment. Only 24 percent of subjects with flat losses of Ն90 dB showed any hearing improvement, and none recovered to normal. Recently, several publications have suggested that intratympanic steroid administration can achieve higher inner ear drug concentrations than the oral route and may be able to salvage hearing that does not respond to primary oral steroid therapy (25) (26) (27) . All treatment series have indicated that earlier initiation of treatment was associated with better hearing outcome.
There have been two randomized controlled trials of specific antiviral therapy (28, 29) . Both these studies failed to show any benefit of adding antiviral drugs to oral steroids alone. Several randomized controlled trials have evaluated the efficacy of vasodilators as primary SSNHL therapy. Fisch reported that inhalation of the central nervous system vasodilator carbogen yielded significantly better hearing outcome than the intravenous anti-vasospastic/volume expander combination of papaverine and dextran (30) . However, subsequent studies of carbogen versus anticoagulant therapy (31) and carbogen versus steroid versus placebo (32) failed to show any benefit of carbogen vasodilatation over placebo or other therapies.
MATERIALS AND METHODS

Inclusion criteria
We retrospectively reviewed 10 years' SSNHL experience at Massachusetts Eye and Ear Infirmary, from August 1990, through March 2001. Initial case retrieval was from the diagnostic coding records of the Massachusetts Eye and Ear Infirmary Otology Service, yielding 997 cases. Our diagnostic criteria ruled out cases with a history of Ménière's syndrome in either ear, previous ear surgery of any kind, blunt or penetrating ear trauma, barotrauma, or acoustic trauma immediately preceding SSNHL, luetic deafness according to criteria outlined by Darmstadt and Harris (33) , genetic SNHL with strong family history, and craniofacial anomalies or known temporal bone malformations as revealed by CT scanning. After exclusion of incorrect coding, incomplete audiometric records, cases that did not meet our diagnostic and audiometric inclusion criteria, and cases where we could not adequately determine the type or timing of therapy, 318 cases were available for review. All these patients experienced an idiopathic unilateral SNHL that developed within 72 hours. They all had Ն25 dB hearing loss at three consecutive frequencies. They all had timely audiograms before and after oral steroid therapy. Steroid treatment was administered within one month of SSNHL onset in 266 of these cases, and no treatment was administered in the remaining 52 cases. Reasons why 52 cases were not treated included patient refusal of therapy, pregnancy, and medical contraindication to use of immunosuppressive drugs.
Audiometric data
Patients were evaluated by certified audiologists using methods standardized for pure tone threshold audiometry (34, 35) . Speech intelligibility was evaluated using standard lists of monosyllables (CID W-22)(36). Pure Tone Average (PTA) was calculated as the average of thresholds at .5, 1, 2, and 4 KHz. Dummy coding was applied such that pretreatment thresholds evaluated as "out at limits" by the audiologist were coded as present at the highest test level. This served to allow comparison with later improved thresholds with the bias toward minimizing the size of the effect. Posttreatment thresholds, still "out at limits" were coded so that no change is seen, that is, no effect strictly due to varying equipment limits was allowed. Some cases reflect the standard audiologic practice of attempting the test and finding no usable speech percept. In such cases, word recognition scores were dummy coded such that pretreatment notes of "could not test" were coded as 0 percent to allow comparison with posttreatment improvements.
Cases with the notation "did not test," or with missing speech data, were not included by dummy coding. Since word recognition scores reflect an accumulation of binary results (correct vs. incorrect), the expected distribution is not normal but binomial in nature. As a result, no single value accurately reflects a significant confidence interval. Thornton and Raffin (37) have published a table for comparison of any two word recognition scores at the p < 0.05 level of confidence, and that table was used in these analyses.
Second-Pass analysis
While the entire data series of 318 cases is presented to describe the clinical presentation, a second-pass analysis was performed in which cases of low frequency hearing loss were excluded, and only those cases with a PTA of 60 dB or worse at initial diagnosis were included. The low frequency cases were removed to avoid possible overlap with cases where the pathophysiology was related to Ménière's syndrome. The less severe cases were removed for two reasons. First, it is hypothesized that cases Ն60 dB PTA may better reflect a singular viral mechanism (12) , and second, this manipulation was felt to be necessary statistically to avoid a floor effect imposed by the use of the PTA. This floor effect arises from the fact that the amount of possible recovery is related to the initial severity of the presentation (38) . That is, a patient with a PTA of 30 dB can only recover (approach 0 dB HL) by about that amount, while a person with a presenting PTA of 60 dB can recover "twice as much". With a treatment recovery effect size estimated a priori from the literature of about 25 dB PTA (with approximately 25 dB SD) (12) , effects are only expected to emerge from a PTAbased analysis in cases with initial PTA well over 50 dB. In addition, there is an a priori level of recovery expected in untreated cases as well, which is estimated to be approximately 15 dB (SD 20) (28) . Again, this fact gives rise to a "noise floor" of spontaneous recovery that must be exceeded by any analysis showing an effect. To do so, the individual cases must begin with a severity large enough to allow recovery (in dB PTA) larger than the expected floor effect. These second-pass criteria reduced the data set to 161, with 139 treated and 22 untreated patients. Since we do not have audiograms from before onset of subjects' SSNHL, "return to baseline" cannot be assessed as an outcome. In both first and second pass analyses, hearing recovery is described in terms of improvement relative to the first available audiogram after onset of SSNHL.
RESULTS
Clinical presentation
A total of 318 patients were included using the sudden sensory hearing loss criteria and were used to describe the general clinical presentation. The initial severity of loss this population is spread across a range from 8.75 dB PTA (i.e., only 4, 6, and 8 KHz affected) to completely dead ears. Fifty-two percent of cases presented with severe-to-profound hearing loss (PTA Ն 60 dB HL). Sex distribution was equal, with 49.9 percent of patients male and 50.1 percent female. Ages ranged from 13 to 89 years and are displayed versus initial severity (dB PTA) in Figure 1 . This figure shows all severities evenly distributed across all ages. Figure 2 shows a categorization of the audiogram types, with flat losses and profound losses predominating (60% of cases). Sudden sensory loss is a unilateral disease, and so, its effect on the life of the patient depends on the status of the contralateral ear. In this series, 61 percent of cases showed normal or near-normal thresholds on the contralateral side, 34 percent had moderate or severe contralateral loss, and in 5 percent of cases, the affected ear was actually the better ear.
Hearing Recovery I: All Subjects
Of all cases presenting, 318 had sufficient data for a comparison of pre-versus posttreatment PTA. There were 266 cases treated with steroids versus 52 who were not treated. All cases are presented in Figure 3 . The mean improvement in PTA for the treatment group was 16.2 dB (SD 30), versus an improvement of 11.7 dB (SD 18) for the untreated group. When all cases were included, the effect (change in PTA) of treatment with steroids did not reach significance (p > .1).
Hearing Recovery II: Severe Losses
A second pass analysis was performed excluding cases of low frequency hearing loss and cases with PTA <60
FIG. 1. Severity in dB PTA is shown versus patient age at initial presentation.
There is a very large spread of initial presenting severity. No significant age effects are noted. dB HL. This pass included 161 patients with 139 treated and 22 not treated. Figure 3 shows this as the exclusion of the less severe cases in the shaded area. With these more stringent criteria, PTA improvement in the treated group was 28.0 dB (SD 24) and in the untreated group was 12.9 dB (SD 23). The effect of treatment in this analysis was significant (p < .01).
Speech intelligibility
The speech intelligibility results are shown in Table 1 . In the upper panel, all patients are included. Speech intelligibility was significantly improved more often in the treated than in the untreated cases (p < .03). In the lower panel, the same analysis is shown for the second pass with exclusion of low frequency cases and those with PTA <60 dB HL. In this group with more severe hearing loss, the steroid treatment effect is slightly larger (p < .02).
DISCUSSION
Recovery with oral corticosteroids
This study shows significant (p < .01) improvement in hearing recovery with the use of oral corticosteroids in cases of severe-to-profound SSNHL. This effect is not evident when less severe losses (< 60 dB PTA) are included, due at least in part to a statistical floor effect. Our results are consistent with those reported in other series where the effects of comparable treatment were analyzed. The data in this study were collected so as to best capture the magnitude of recovery (in combined dB PTA). We have also taken our raw data and used the outcome criteria of other published SSNHL series to compare results across studies. Wilson et al. used a criteria for recovery of 50 percent of the initial loss (12) . Using recovery to near-normal levels (PTA <30 dB) as a comparison, our study shows fewer treated patients recovering (Wilson et al., 61% versus the current study at 46%). Using the criteria of Wilson et al. (12) on our second pass (more severe cases) yields a recovery rate of 55 percent. Similar criteria (recovery of 50% of loss) were used by Tucci et al. (39) . Their placebo group (oral steroid only) also showed a higher percentage of recovery (65%) than ours (46%). Cinamon et al. used a 15 dB
FIG. 2.
The distribution of audiogram configurations (slopes) at initial presentation. The majority are flat audiograms followed-up in prevalence by profound losses (corner audiograms). Cases with "Hi Freq" showed severe slopes (> 30 dB per octave) affecting a clear cut off frequency (2, 3, or 4 KHz), while those with "Sloping" loss had gentler slopes, often affecting most frequencies. The 12 percent of cases with "Lo Freq" hearing loss affecting low frequencies significantly more than highs were excluded from the second pass analysis (along with cases <60 dB PTA) since these may reflect a different clinical entity, such as Mé-niè re's Disease.
FIG. 3.
Improvement in PTA is shown versus the initial PTA on presentation. Treated patients are shown with filled diamonds, untreated patients with open circles. Both the presentation and outcome for all cases can be appreciated. Improvement (change in dB PTA) appears as a negative number on the vertical axis because follow-up PTA is smaller than presenting PTA. Thus greater improvements are near the bottom of the graph. The diagonal line indicates perfect recovery, in which the initial PTA and the magnitude of improvement are equal (i.e. follow-up PTA of 0 dB). This "floor effect" restricts the magnitude of improvement when the initial PTA is good. The shaded wedge-shaped region in the upper left of this plot indicates subjects with initial PTA <60 dB. These cases were all excluded from the second pass data analysis (see Method and Results). In this subpopulation, the treated and untreated cases cannot be differentiated statistically. This does not prove that these cases did not improve, only that treatment effect cannot be distinguished from spontaneous recovery by measuring change in PTA. change criterion for recovery (32) . Applying this to our dataset shows recovery in 51 percent of cases, compared with 60 percent in the oral steroid treated subjects of Cinamon et al. However, with only the more severe cases included, this rises to a comparable 66 percent recovery rate in the current study. Stokroos, et. al (28) showed 2-week PTA improvement of 24 dB ("Fletcher's 3-frequency" (40)), which is comparable to the 28.5 dB shown in this study in a similar time frame. Overall, recovery with oral steroid treatment occurred in fewer cases in this cohort than in others that have been reported, but the effect of treatment remained significant.
Spontaneous recovery rates
During the period of review of this study, 52 patients with SSNHL went without steroid therapy, allowing a comparison of the spontaneous recovery rate with other investigations. Wilson, et al. (12) reported a spontaneous recovery rate of 32 percent in untreated patients, comparable to the rate of 31 percent found in this study using the same criteria. Cinamon et al. (32) reported results in two placebo groups and, when these are combined, they yield a recovery rate of 55 percent-slightly greater than the rate of 43 percent we observed using the same criteria with our dataset. Mattox and Simmons reported a spontaneous recovery rate of 65 percent (4). This seems fairly high, and is related to the criteria used (Good recovery ‫ס‬ final PTA <40 dB). Using this same criterion, the untreated cohort in our study showed a spontaneous recovery rate of 53 percent. In general, while criteria and methods may vary, it seems that the untreated group in this study does not differ substantially from the performance of untreated groups reported elsewhere.
Limitations of this study
Due to the retrospective nature of the data acquisition, it was often impossible to ascertain why steroid therapy was not administered to members of the untreated group. Available records indicate an assortment of medical contraindications to corticosteroids such as severe psychiatric disease, active peptic ulcer disease, and allergic reaction to previous corticosteroids. Occasional patients simply declined therapy. It is conceivable that some medical comorbidities could skew the outcome and lead to over-or underestimate of the actual spontaneous recovery rate. Likewise, there could be cases of Ménière's syndrome, demyelinating disease, or other conditions that were mistakenly diagnosed as SSNHL. Presumably this ascertainment bias afflicts both treated and untreated cohorts equally.
As a retrospective analysis, this study lacks formal controls and should be interpreted as a description of a large clinical series. In terms of the effects of oral corticosteroids, most patients were treated during this period, and there is a large difference between the sizes of the treated and untreated groups. This difference is not desirable, but it is accounted for by the statistic used to determine significance (Satterthwaite's t Test for unequal variance; SAS Institute). The exclusion criteria for both the first and second pass analyses of this study were very strict, and it is likely that cases that could possibly have been informative were excluded. The first pass removed both cases with any diagnostic indication other than SSNHL and also applied very strict data requirements for completed audiograms. The second pass further reduced the dataset by retaining only losses with the presenting PTA Ն60 dB HL. The reason for restricting the data to cases presenting worse than 60 dB PTA has been discussed above in relation to both pathophysiology and statistical floor effects (see Methods). It should be pointed out that this restriction allows for a clear statistical effect, but it does not prove that there was no recovery in those patients excluded. Because PTA averages threshold data, it is possible for SSNHL to be diagnosed in cases where the PTA is decreased only a few decibels. For example, if a significant drop is seen at 4 KHz and above, the patient will report a sudden loss, and the change in PTA will be small. If there is good recovery, the change will also be small, even if the treatment had the desired effect. This constraint had the further effect of eliminating subjects who exclusively had low frequency or high frequency SSNHL but retained those with significant mid-frequency losses. The exclusion of frequency extremes has two benefits-exclusion of low frequency SSNHL reduces ascertainment bias that might arise from mistakenly including patients with Mé-nière's syndrome, and exclusion of high frequency SSNHL lessens the likelihood of overestimating treatment benefit by including patients who might have threshold shift but no functional benefit to speech recognition.
CONCLUSIONS
While SSNHL is not one of the most common causes of deafness, it is disproportionately important because it is an example of reversible sensorineural hearing loss. Reversible sensorineural losses are natural experiments, giving investigators unique windows into basic physiology and pathophysiology of the inner ear. By studying this disease and its response to the proposed treatments, we are likely to learn things that will shed light on the role of inflammation and its treatment in the inner ear. In terms of this study, our findings agree with other studies showing that steroids are effective in promoting recovery in SSNHL. This benefit is seen for both threshold and word recognition. It is most clearly demonstrated in cases of moderate-to-severe SSNHL. Steroid treatment of SSNHL may act in several ways, producing an antiviral effect, a local or systemic immunosuppressive effect, a direct anti-inflammatory effect, or possibly though an effect on inner ear homeostasis. Much work remains to elucidate these mechanisms and optimize treatment of this common otological emergency.
